YnnoMed is a pharmaceutical company dedicated to addressing the unmet medical needs of new antimicrobial agents tackling antimicrobial resistance. Our goal is to design and develop first-in-class antimicrobial medicines that are effective against current antibiotic-resistant infections. Unlike most antibiotic candidates under development that are derivatives of existing antibiotics, YnnoMed pioneered the development of bacterial transcription inhibitors as new antimicrobial agents. With the aid of our in-house developed AI-assisted technology, we have generated several pipelines of novel antibiotic candidates with unprecedented protein targets, new chemical structures, and unique modes-of-action. The leading series show strong prospects for clinical use with highly promising antimicrobial properties, including the capacity to effectively kill drug-resistant bacteria, low cytotoxicity, and no detectable development of resistance. Apart from drug development, we also work on hit-compound identification and structure optimisation for other areas of biomedical research. By accelerating the R&D efforts of both academia and the pharmaceutical industry, our products are expected to enrich the future drug market.

2022

Biotech

TSSSU Company